Genetics in degenerative dementia: Current status and applicability

Alzheimer Disease and Associated Disorders

Volumn 28, Issue 3, 2014, Pages 199-205

  Bruni, Amalia C ^a   Conidi, Maria E ^a   Bernardi, Livia ^a  

^a ASL   (Italy)

Author keywords

Alzheimer disease; frontotemporal dementia; genetics; Lewy body disease

Indexed keywords

ALZHEIMER DISEASE; CLINICAL PRACTICE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETICS; HUMAN; MAJOR GENE; META ANALYSIS (TOPIC); MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); DEGENERATIVE DISEASE; GENETIC PREDISPOSITION;

DEMENTIA; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84907140873     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000046     Document Type: Review

References (95)

1. Frisoni GB, Fox NC, Jack CR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67-77.
2. Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol. 2005;15:463-471.
3. Alzheimer Europe. Dementia in Europe Yearbooks 2008. Luxemburg: Alzheimer Europe; 2008.
4. Di Carlo A, Baldereschi M, Amaducci L, et al. ILSA Working Group. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002;50:41-48.
5. van Duijn CM, Stijnen T, Hofman A. Risk factors for Alzheimer's disease: Overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(suppl 2):S4-S12.
6. Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10:231-239.
7. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375-398.
8. Kumar-Singh S, Van Broeckhoven C. Frontotemporal lobar degeneration: Current concepts in the light of recent advances. Brain Pathol. 2007;17:104-114.
9. Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: Patient characteristics and prevalence estimates from a population-based study. Brain. 2003;126:2016-2022.
10. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34:561-566.
11. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
12. Foncin JF, Salmon D, Supino-Viterbo V, et al. Alzheimer's presenile dementia transmitted in an extended kindred. Rev Neurol (Paris). 1985;141:194-202.
13. Rainero I, Bergamini L, Bruni AC, et al. A new Italian pedigree with early-onset Alzheimer's disease. J Geriatr Psychiatry Neurol. 1994;7:28-32.
14. Bruni AC, Bernardi L, Colao R, et al. Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation. Neurology. 2010;74:798-806.
15. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349: 704-706.
16. Wisniewski T, Dowjat WK, Buxbaum JD, et al. A novel Polish presenilin-1 mutation (P117L) is associated with familial Alzheimer's disease and leads to death as early as the age of 28 years. Neuroreport. 1998;9:217-221.
17. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and-2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43-51.
18. Edwards-Lee T, Ringman JM, Chung J, et al. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology. 2005;64:377-379.
19. Kamino K, Orr HT, Payami H, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992;51:998-1014.
20. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet. 1996;5:985-988.
21. Finckh U, Alberici A, Antoniazzi M, et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology. 2000;54:2006-2008.
22. Zekanowski C, Styczyń ska M, Pep"oń ska B, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol. 2003;184:991-996.
23. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012;33:1340-1344.
24. Obici L, Demarchi A, de Rosa G, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol. 2005;58:639-644.
25. Maat-Schieman ML, van Duinen SG, Bornebroek M, et al. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II-a review of histopathological aspects. Brain Pathol. 1996;6:115-120.
26. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977-2983.
27. Rossi G, Giaccone G, Maletta R, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology. 2004;63:910-912.
28. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815-825.
29. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240-250.
30. Neumann M, Diekmann S, Bertsch U, et al. Novel G335V mutation in the tau gene associated with early onset familial frontotemporal dementia. Neurogenetics. 2005;6:91-95.
31. Hayashi S, Toyoshima Y, Hasegawa M, et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol. 2002;51:525-530.
32. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442: 916-919.
33. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920-924.
34. Ahmed Z, Mackenzie IR, Hutton ML, et al. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation. 2007;11:4-7.
35. Beck J, Rohrer JD, Campbell T, et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain. 2008;131:706-720.
36. Wang J, Van Damme P, Cruchaga C, et al. Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem. 2010;112:1305-1315.
37. Coppola G, Karydas A, Rademakers R, et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol. 2008;64:92-96.
38. Ghidoni R, Benussi L, Glionna M, et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235-1239.
39. Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009; 132:583-591.
40. Le Ber I, Camuzat A, Hannequin D, et al. French research network on FTD/FTD-MND. Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study. Brain. 2008;131:732-746.
41. Leverenz JB, Yu CE, Montine TJ, et al. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain. 2007;130: 1360-1374.
42. Bruni AC, Momeni P, Bernardi L, et al. Heterogeneity within a large kindred with frontotemporal dementia: A novel progranulin mutation. Neurology. 2007;69:140-147.
43. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257-268.
44. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245-256.
45. Zarranz JJ, Alegre J, Gó mez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164-173.
46. Morfis L, Cordato DJ. Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation. J Clin Neurosci. 2006;13:942-944.
47. Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology. 2004;63: 805-811.
48. Piscopo P, Marcon G, Piras MR, et al. A novel PSEN2 mutation associated with a peculiar phenotype. Neurology. 2008;70:1549-1554.
49. Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J Clin Invest. 1999;104:1175-1179.
50. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168-177.
51. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41: 1088-1093.
52. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-1099.
53. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43: 429-435.
54. Hong MG, Reynolds CA, Feldman AL, et al. Genome-wide and gene-based association implicates FRMD6 in Alzheimer disease. Hum Mutat. 2012;33:521-529.
55. Liu G, Jiang Y, Wang P, et al. Cell adhesion molecules contribute to Alzheimer's disease: Multiple pathway analyses of two genomewide association studies. J Neurochem. 2012;120:190-198.
56. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
57. Bernardi L, Maletta RG, Tomaino C, et al. The effects of APOE and tau gene variability on risk of frontotemporal dementia. Neurobiol Aging. 2006;27:702-709.
58. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 1994;44:1950-1951.
59. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977-1981.
60. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5644-5651.
61. Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 2010;10:375-384.
62. Verpillat P, Camuzat A, Hannequin D, et al. Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol. 2002;59:935-939.
63. Ghidoni R, Signorini S, Barbiero L, et al. The H2 MAPT haplotype is associated with familial frontotemporal dementia. Neurobiol Dis. 2006;22:357-362.
64. Myers AJ, Kaleem M, Marlowe L, et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet. 2005;14:2399-2404.
65. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol. 1995;37:110-112.
66. Tomaino C, Bernardi L, Anfossi M, et al. Presenilin 2 Ser130Leu mutation in a case of late-onset "sporadic" Alzheimer's disease. J Neurol. 2007;254:391-393.
67. Spina S, Murrell JR, Yoshida H, et al. The novel Tau mutation G335S: Clinical, neuropathological and molecular characterization. Acta Neuropathol. 2007;113:461-470.
68. Ghetti B, Spina S, Murrell JR, et al. In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. Neurodegener Dis. 2008;5:215-217.
69. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science. 2009;323:1473-1477.
70. Anfossi M, Vuono R, Maletta R, et al. Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. Neurobiol Aging. 2011;32:757.e1-757. e11.
71. Mead S, PoulterM, Beck J, et al. Inherited prion disease with six octapeptide repeat insertional mutation-molecular analysis of phenotypic heterogeneity. Brain. 2006;129:2297-2317.
72. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PSEN1 kindred. Ann Neurol. 2003;54:163-169.
73. Sorbi S, Nacmias B, Forleo P, et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol. 1995;38:124-127.
74. Anfossi M, Bernardi L, Gallo M, et al. MAPT V363I variation in a sporadic case of frontotemporal dementia: Variable penetrant mutation or rare polymorphism? Alzheimer Dis Assoc Disord. 2011;25:96-99.
75. Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76:467-474.
76. Tedde A, Forleo P, Nacmias B, et al. A presenilin-1 mutation (Leu392Pro) in a familial AD kindred with psychiatric symptoms at onset. Neurology. 2000;55:1590-1591.
77. Zekanowski C, Golan MP, Krzyśko KA, et al. Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: Genetic and bioinformatic assessment. Exp Neurol. 2006;200:82-88.
78. Bernardi L, Tomaino C, Anfossi M, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging. 2009;30:1825-1833.
79. Binetti G, Signorini S, Squitti R, et al. Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol. 2003;54:832-836.
80. Ishikawa A, Piao YS, Miyashita A, et al. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol. 2005;57:429-434.
81. Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol. 2011;69:712-720.
82. Nitrini R, Teixeira da Silva LS, Rosemberg S, et al. Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17. Arq Neuropsiquiatr. 2001;59(2-A): 161-164.
83. Clerici F, Elia A, Girotti F, et al. Atypical presentation of Creutzfeldt-Jakob disease: The first Italian case associated with E196K mutation in the PRNP gene. J Neurol Sci. 2008; 275:145-147.
84. Giovagnoli AR, Di Fede G, Aresi A, et al. Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family. Neurol Sci. 2008;29:405-410.
85. Bernardi L, Anfossi M, Gallo M, et al. PSEN1 and PRNP gene mutations co-occurrence makes onset very early in a family with FTD phenotype. J Alzheimers Dis. 2011;24: 415-419.
86. Koide T, Ohtake H, Nakajima T, et al. A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. Neurology. 2002;59:1619-1621.
87. Santos-Rebouças CB, Abdalla CB, Baldi FJ, et al. Cooccurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test. 2008;12:471-473.
88. Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: Mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2008;30:847-856.
89. Karlstrom H, Brooks WS, Kwok JB, et al. Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem. 2008;104:573-583.
90. Bernardi L, Geracitano S, Colao R, et al. AbetaPP A713T mutation in late onset Alzheimer's disease with cerebrovascular lesions. J Alzheimers Dis. 2009;17:383-389.
91. Spina S, Farlow MR, Unverzagt FW, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: Characterization of the MSTD family. Brain. 2008;131:72-89.
92. Gallo M, Tomaino C, Puccio G, et al. Novel MAPT Val75Ala mutation and PSEN2 Arg62Hys in two siblings with frontotemporal dementia. Neurol Sci. 2010;31:65-70.
93. Brouwers N, Sleegers K, Engelborghs S, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71:656-664.
94. Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-T (Arg493X) mutation: An international initiative. Lancet Neurol. 2007;6:857-868.
95. Singleton AB, Farrer M, Johnson J, et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302:841.